

Info Sheet for Technical description

No. 0005

Organization

* Mandatoty fields

Name of Organization*	Innovacell Inc.		
Address, City, States, Zip, Country*	MEGURO VILLA GARDEN 5F, 3-5-11 KAMIOSAKI SHINAGAWA-KU, TOKYO, 141-0021 Japan		
URL	https://www.innovacell.co.jp/		
Brief Descriptions of Organization* (Approx. 100 words)	Innovacell was founded in 2000 as a spin-off from the Medical University of Innsbruck in Austria. In 2021, the company relocated its headquarters to Tokyo, Japan, and now operates as a group with Innovacell K.K. in Japan and Innovacell GmbH in Austria. Its pipeline includes two late-stage clinical programs, ICEF15 and ICES13, and one pre-clinical program, ICEF16, all targeting various forms of incontinence. ICEF15, an autologous skeletal myoblast cell therapy, is in a multi-regional Phase III trial across Europe and Japan. In 2025, Innovacell successfully raised JPY 7.3 billion in Series D financing from global investors.		
Contact address	Name*	Colin Lee Novick	
	Department* / Position	Co-CEO	
	E-mail* / TEL	colin@innovacell.co.jp/080-4422-0403 Assistant email : eimi.tamura@innovacell.co.jp	

What kind of technology do you want to offer? *

- ☒ **A.** Clinical Development Pipelines
- Please see **Sheet [A]**
- ☐ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc.
- Please see **Sheet [B]**
- ☐ **C.** Platform Technologies(*) that are not included in the above (Group B)
- Please see **Sheet [C]**
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- ☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- ☐ Yes
- ☒ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☐ Series A
- ☐ Series B
- ☐ Series C
- ☒ Series D or further advenced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☒ Yes	
☐ No	

Filled in by*

Date*

Colin Lee Novick

2025/8/28

Sheet [A] Clinical Development Pipelines**Info Sheet for Technical overview**

No. A-0005-2

* Mandatoty fields

Title*ICES13**Development Phase***

- | | | |
|--|--|---|
| ☐ Basic Research | ☐ Drug Discovery | ☐ Pre-Clinical |
| ☒ Clinical Trial (Phase I) | ☐ Clinical Trial (Phase II) | ☐ Clinical Trial (Phase III) |
| ☐ Review | ☐ Others | |

Diesease Area*

- | | | |
|--|---|---|
| ☐ Cancer | ☐ Central nervous system | ☐ Ophthalmology |
| ☐ Musculoskeletal | ☐ Endocrine / Metabolism | ☐ Cardiovascular |
| ☒ Urogenital | ☐ Digestive organ | ☐ Blood |
| ☐ Infection | ☐ Dermatology | ☐ Immunity |
| ☐ Otolarngology | ☐ Respiratory | ☐ Others |

Description*

Autologous cell therapy for treating stress urinary incontinence

Publications:

- <https://pubmed.ncbi.nlm.nih.gov/23111866/>
- <https://pubmed.ncbi.nlm.nih.gov/22342057/>
- <https://pubmed.ncbi.nlm.nih.gov/39976680/>

Filled in by*

Colin Lee Novick

Date*

2025/8/28